OTC · CLCS
Cell Source, Inc.
$0.53+$0.06 (+13.97%)
Cell Source, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.45% below the high.
Loading market information…
OTC · BTCY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Biotricity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biotricity, Inc.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biotricity, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring capabilities to the medical, healthcare, and individual consumer markets, encompassing both diagnostic tools and ongoing management support for chronic and lifestyle-related conditions. Among its key offerings are the Bioflux mobile cardiac telemetry solution, an integrated ECG device, alongside specialized ECG analysis software designed to process and synthesize patient heart rhythm data, complemented by various software components.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $3.70M+2.78% vs estimate |
| Q3 2025 | Feb 20, 2025 | -$0.05+54.55% vs estimate | $3.60M0.0% vs estimate |
|---|
| Q2 2025 | Nov 14, 2024 | -$0.07+36.36% vs estimate | $3.30M0.0% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.53+$0.06 (+13.97%)
Cell Source, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.45% below the high.
$0.04+$0.01 (+33.33%)
CareView Communications, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.15-$0.00 (-1.36%)
Guided Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.15% below the high.
CA$0.08-CA$0.01 (-5.88%)
VentriPoint Diagnostics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 57.89% below the high.
$0.04+$0.00 (+8.82%)
United Health Products, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.17% below the high.
$0.02-$0.00 (-1.32%)
ALR Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.78% below the high.
CA$0.12-CA$0.01 (-7.69%)
Aurora Spine Corporation’s quoted price sits in the lower half of its reported 52-week range, 63.08% below the high.
$0.05$0.00 (0.0%)
Gemina Laboratories Ltd.’s quoted price sits in the lower half of its reported 52-week range, 85.46% below the high.
